Literature DB >> 16277545

Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels.

Marieke E van Velden1, Johan L Severens, Annoesjka Novak.   

Abstract

Given the potential role of economic information in healthcare decision making, it is of interest to assess its influence on decisions at a national or regional level (macro level), at a healthcare facility level (meso level) and at the healthcare provider level (micro level). This literature review summarises 36 empirical studies that examined the influence of economic evaluations on these three healthcare decision-making levels. Economic evaluations are considered useful and important; however, their direct influence on decision making (instrumental use) is moderate, especially at the macro and micro levels. A major influence was observed at the meso level, leading to the conclusion that economic evaluations have the most pronounced influence on decision making within healthcare organisations. However, unexpectedly, our literature search did not reveal an empirical study analysing the considerable influence of economic evaluations on decisions by the National Institute of Health and Clinical Excellence in the UK. Our findings indicate that results of economic evaluations cannot be considered the dominant decision criterion for healthcare decision makers at either the macro, meso or micro levels. Enlightenment use (where scientific evidence provides a background of information, ideas and concepts that affect the way policy makers view problems and solutions) of economic evaluations in decision making remains to be proven.

Mesh:

Year:  2005        PMID: 16277545     DOI: 10.2165/00019053-200523110-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  37 in total

Review 1.  Economic evaluation in health care: the usefulness of research guidelines.

Authors:  J L Severens
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2001-01       Impact factor: 2.435

2.  Pharmacoeconomics and clinical practice guidelines. A survey of attitudes in Swedish formulary committees.

Authors:  A Anell; P Svarvar
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

3.  Research into the use of health economics in decision making in the United Kingdom--Phase II. Is health economics 'for good or evil'?

Authors:  T Duthie; P Trueman; J Chancellor; L Diez
Journal:  Health Policy       Date:  1999-01       Impact factor: 2.980

4.  Economic evaluations of drug therapy: attitudes of primary care prescribing advisers in Great Britain.

Authors:  T Walley; S Barton; J Cooke; M Drummond
Journal:  Health Policy       Date:  1997-07       Impact factor: 2.980

5.  The review process used by US health care plans to evaluate new medical technology for coverage.

Authors:  C A Steiner; N R Powe; G F Anderson; A Das
Journal:  J Gen Intern Med       Date:  1996-05       Impact factor: 5.128

6.  Managed care pharmacy, socioeconomic assessments and drug adoption decisions.

Authors:  A Lyles; B R Luce; A M Rentz
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

7.  The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States.

Authors:  B R Luce; R E Brown
Journal:  Int J Technol Assess Health Care       Date:  1995       Impact factor: 2.188

8.  Use of pharmacoeconomic data in making hospital formulary decisions.

Authors:  Folakemi T Odedina; Johanna Sullivan; Rowena Nash; C Denise Clemmons
Journal:  Am J Health Syst Pharm       Date:  2002-08-01       Impact factor: 2.637

9.  Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy.

Authors:  Doruk Erkan; Yusuf Yazici; Melanie J Harrison; Stephen A Paget
Journal:  Arthritis Rheum       Date:  2002-06-15

10.  Use of formal benefit/cost evaluations in health system decision making.

Authors:  Bernard S Bloom
Journal:  Am J Manag Care       Date:  2004-05       Impact factor: 2.229

View more
  15 in total

1.  Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.

Authors:  Ties Hoomans; Johan L Severens; Nicole van der Roer; Gepke O Delwel
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

2.  Economic evidence at the local level : options for making it more useful.

Authors:  Kees van Gool; Gisselle Gallego; Marion Haas; Rosalie Viney; Jane Hall; Robyn Ward
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Loss aversion and cost effectiveness of healthcare programmes: whose aversion counts anyway?

Authors:  Johan L Severens; J L Hans Severens
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  The use (or rather the non-use) of cost-effectiveness data in priority setting decisions - are we underestimating the barriers to using health economics in real world priority setting decisions?: Comment on "Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden".

Authors:  Sandra T Erntoft
Journal:  Int J Health Policy Manag       Date:  2015-02-10

5.  Management of Hospital Formularies in Ontario: Challenges within a Local Health Integration Network.

Authors:  Natasha Burke; James M Bowen; Sue Troyan; Jathishinie Jegathisawaran; Carolyn Gosse; Marita Tonkin; Sandra Kagoma; Ron Goeree; Anne Holbrook
Journal:  Can J Hosp Pharm       Date:  2016-06-30

6.  Home Telemonitoring Technology for Patients With Heart Failure: Cost-Consequence Analysis of a Pilot Study.

Authors:  Glory Apantaku; Craig Mitton; Hubert Wong; Kendall Ho
Journal:  JMIR Form Res       Date:  2022-06-02

7.  The role of economic evaluation in the decision-making process of family physicians: design and methods of a qualitative embedded multiple-case study.

Authors:  Chantale Lessard; André-Pierre Contandriopoulos; Marie-Dominique Beaulieu
Journal:  BMC Fam Pract       Date:  2009-02-11       Impact factor: 2.497

8.  From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking.

Authors:  Lalla Aïda Guindo; Monika Wagner; Rob Baltussen; Donna Rindress; Janine van Til; Paul Kind; Mireille M Goetghebeur
Journal:  Cost Eff Resour Alloc       Date:  2012-07-18

9.  A randomised trial comparing the cost effectiveness of different emergency department healthcare professionals in soft tissue injury management.

Authors:  Carey Middleton McClellan; Fiona Cramp; Jane Powell; Jonathan Richard Benger
Journal:  BMJ Open       Date:  2013-01-03       Impact factor: 2.692

10.  Performance of the EQ-5D and the EQ-5D+C in elderly patients with cognitive impairments.

Authors:  Claire A G Wolfs; Carmen D Dirksen; Alfons Kessels; Daniëlle C M Willems; Frans R J Verhey; Johan L Severens
Journal:  Health Qual Life Outcomes       Date:  2007-06-14       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.